Enhanced antitumor efficacy of an oncolytic herpes simplex virus expressing an endostatin-angiostatin fusion gene in human glioblastoma stem cell xenografts

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Zhang, Guobin ^a   Jin, Guishan ^b   Nie, Xiutao ^c   Mi, Ruifang ^b   Zhu, Guidong ^b   Jia, William ^d   Liu, Fusheng ^b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c Rizhao City People's Hospital   (China)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOSTATIN ENDOSTATIN FUSION PROTEIN; ONCOLYTIC HERPES VIRUS; RECOMBINANT ENDOSTATIN; UNCLASSIFIED DRUG; ANGIOSTATIN; ENDOSTATIN; HYBRID PROTEIN; ONCOLYTIC VIRUS;

ANGIOSTATIN GENE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER STEM CELL; CANCER SURVIVAL; CAPILLARY DENSITY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; ENDOSTATIN GENE; FUSION GENE; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MICROVASCULARIZATION; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; SINGLE DRUG DOSE; TUMOR VOLUME; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; BRAIN NEOPLASMS; CANCER TRANSPLANTATION; GENE THERAPY; GENETICS; NEOVASCULARIZATION, PATHOLOGIC; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; SIMPLEXVIRUS; TRANSPLANTATION; TUMOR CELL CULTURE; VASCULARIZATION;

ANGIOSTATINS; ANIMALS; BRAIN NEOPLASMS; ENDOSTATINS; GENETIC THERAPY; GLIOBLASTOMA; HUMANS; MALE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASTIC STEM CELLS; NEOVASCULARIZATION, PATHOLOGIC; ONCOLYTIC VIRUSES; RECOMBINANT FUSION PROTEINS; SIMPLEXVIRUS; TUMOR BURDEN; TUMOR CELLS, CULTURED;

EID: 84899690729     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0095872     Document Type: Article

References (42)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996. (Pubitemid 40349501)
2. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, et al. (2004) Identification of human brain tumour initiating cells. Nature 432: 396-401. (Pubitemid 39551674)
3. Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, et al. (2004) Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 64: 7011-7021. (Pubitemid 39331011)
4. Yuan X, Curtin J, Xiong Y, Liu G, Waschsmann-Hogiu S, et al. (2004) Isolation of cancer stem cells from adult glioblastoma multiforme. Oncogene 23: 9392-9400. (Pubitemid 40069671)
5. Zhang X, Zhang W, Mao XG, Zhen HN, Cao WD, et al. (2013) Targeting role of glioma stem cells for glioblastoma multiforme. Curr Med Chem 20: 1974-1984.
6. Bao S, Wu Q, Sathornsumetee S, Hao Y, Li Z, et al. (2006) Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 66: 7843-7848. (Pubitemid 44299144)
7. Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, et al. (2007) A perivascular niche for brain tumor stem cells. Cancer Cell 11: 69-82. (Pubitemid 46054518)
8. Diabira S, Morandi X (2008) Gliomagenesis and neural stem cells: Key role of hypoxia and concept of tumor "neo-niche". Med Hypotheses 70: 96-104. (Pubitemid 350161161)
9. Filatova A, Acker T, Garvalov BK (2013) The cancer stem cell niche(s): the crosstalk between glioma stem cells and their microenvironment. Biochim Biophys Acta 1830: 2496-2508.
10. Scadden DT (2006) The stem-cell niche as an entity of action. Nature 441: 1075-1079.
11. Gilbertson RJ, Rich JN (2007) Making a tumour's bed: glioblastoma stem cells and the vascular niche. Nat Rev Cancer 7: 733-736. (Pubitemid 47463683)
12. Zhou BB, Zhang H, Damelin M, Geles KG, Grindley JC, et al. (2009) Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov 8: 806-823.
13. Moore KA, Lemischka IR (2006) Stem cells and their niches. Science 311: 1880-1885.
14. Pinto A, Redondo A, Zamora P, Castelo B, Espinosa E (2010) Angiogenesis as a therapeutic target in urothelial carcinoma. Anticancer Drugs 21: 890-896.
15. Liu TC, Galanis E, Kirn D (2007) Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Clin Pract Oncol 4: 101-117. (Pubitemid 46189539)
16. Selznick LA, Shamji MF, Fecci P, Gromeier M, Friedman AH, et al. (2008) Molecular strategies for the treatment of malignant glioma-genes, viruses, and vaccines. Neurosurg Rev 31: 141-155, 155.
17. Wakimoto H, Kesari S, Farrell CJ, Curry WJ, Zaupa C, et al. (2009) Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Res 69: 3472-3481.
18. Dey M, Ulasov IV, Lesniak MS (2010) Virotherapy against malignant glioma stem cells. Cancer Lett 289: 1-10.
19. Hardcastle J, Kurozumi K, Dmitrieva N, Sayers MP, Ahmad S, et al. (2010) Enhanced antitumor efficacy of vasculostatin (Vstat120) expressing oncolytic HSV-1. Mol Ther 18: 285-294.
20. Ferrara N, Kerbel RS (2005) Angiogenesis as a therapeutic target. Nature 438: 967-974. (Pubitemid 43093963)
21. Ricci-Vitiani L, Pallini R, Biffoni M, Todaro M, Invernici G, et al. (2010) Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 468: 824-828.
22. Wang R, Chadalavada K, Wilshire J, Kowalik U, Hovinga KE, et al. (2010) Glioblastoma stem-like cells give rise to tumour endothelium. Nature 468: 829-833.
23. Cheng L, Huang Z, Zhou W, Wu Q, Donnola S, et al. (2013) Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. Cell 153: 139-152.
24. Boehm T, Folkman J, Browder T, O'Reilly MS (1997) Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390: 404-407. (Pubitemid 28027321)
25. Zhan Q, Yue W, Hu S (2011) Effect of photodynamic therapy and endostatin on human glioma xenografts in nude mice. Photodiagnosis Photodyn Ther 8: 314-320.
26. Zhu G, Su W, Jin G, Xu F, Hao S, et al. (2011) Glioma stem cells targeted by oncolytic virus carrying endostatin-angiostatin fusion gene and the expression of its exogenous gene in vitro. Brain Res 1390: 59-69.
27. Huszthy PC, Goplen D, Thorsen F, Immervoll H, Wang J, et al. (2008) Oncolytic herpes simplex virus type-1 therapy in a highly infiltrative animal model of human glioblastoma. Clin Cancer Res 14: 1571-1580. (Pubitemid 351413942)
28. Yang CT, Lin YC, Lin CL, Lu J, Bu X, et al. (2005) Oncolytic herpes virus with secretable angiostatic proteins in the treatment of human lung cancer cells. Anticancer Res 25: 2049-2054. (Pubitemid 40904603)
29. Liu JM, Mao BY, Hong S, Liu YH, Wang XJ (2008) The postoperative brain tumour stem cell (BTSC) niche and cancer recurrence. Adv Ther 25: 389-398.
30. Manservigi R, Argnani R, Marconi P (2010) HSV Recombinant Vectors for Gene Therapy. Open Virol J 4: 123-156.
31. Beier D, Hau P, Proescholdt M, Lohmeier A, Wischhusen J, et al. (2007) CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 67: 4010-4015. (Pubitemid 46815044)
32. Candolfi M, Curtin JF, Nichols WS, Muhammad AG, King GD, et al. (2007) Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression. J Neurooncol 85: 133-148. (Pubitemid 47629395)
33. Markert JM, Medlock MD, Rabkin SD, Gillespie GY, Todo T, et al. (2000) Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 7: 867-874. (Pubitemid 30303584)
34. Parker JN, Bauer DF, Cody JJ, Markert JM (2009) Oncolytic viral therapy of malignant glioma. Neurotherapeutics 6: 558-569.
35. Markert JM, Liechty PG, Wang W, Gaston S, Braz E, et al. (2009) Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. Mol Ther 17: 199-207.
36. Kurozumi K, Hardcastle J, Thakur R, Shroll J, Nowicki M, et al. (2008) Oncolytic HSV-1 infection of tumors induces angiogenesis and upregulates CYR61. Mol Ther 16: 1382-1391.
37. Aghi M, Rabkin SD, Martuza RL (2007) Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin- derived peptide. Cancer Res 67: 440-444. (Pubitemid 46192178)
38. Kurozumi K, Hardcastle J, Thakur R, Yang M, Christoforidis G, et al. (2007) Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy. J Natl Cancer Inst 99: 1768-1781. (Pubitemid 351767207)
39. Angarita FA, Acuna SA, Ottolino-Perry K, Zerhouni S, McCart JA (2013) Mounting a strategic offense: fighting tumor vasculature with oncolytic viruses. Trends Mol Med 19: 378-392.
40. Breitbach CJ, De Silva NS, Falls TJ, Aladl U, Evgin L, et al. (2011) Targeting tumor vasculature with an oncolytic virus. Mol Ther 19: 886-894.
41. Li L, Neaves WB (2006) Normal stem cells and cancer stem cells: the niche matters. Cancer Res 66: 4553-4557.
42. Ezhilarasan R, Mohanam I, Govindarajan K, Mohanam S (2007) Glioma cells suppress hypoxia-induced endothelial cell apoptosis and promote the angiogenic process. Int J Oncol 30: 701-707.